BNGO Quote, Financials, Valuation and Earnings

Azenta has a net margin of -728.57% compared to Bionano Genomics's net margin of -2.93%. Bionano Genomics's return on equity of -158.95% beat Azenta's return on equity of -7.49%.

Bionano Genomics has a consensus price target of --, signalling upside risk potential of 396.77%. On the other hand Azenta has an analysts' consensus of -- which suggests that it could grow by 12.24%. Given that Bionano Genomics has higher upside potential than Azenta, analysts believe Bionano Genomics is more attractive than Azenta.

Bionano Genomics has a beta of 2.279, which suggesting that the stock is 127.944% more volatile than S&P 500. In comparison Azenta has a beta of 1.493, suggesting its more volatile than the S&P 500 by 49.318%.

Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bionano Genomics pays -- of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend.

Bionano Genomics quarterly revenues are $6.1M, which are smaller than Azenta quarterly revenues of $170.1M. Bionano Genomics's net income of -$44.2M is lower than Azenta's net income of -$5M. Notably, Bionano Genomics's price-to-earnings ratio is -- while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.28x versus 4.09x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of -728.57% compared to Bionano Genomics's net margin of 4.73%. Bionano Genomics's return on equity of -158.95% beat Bruker's return on equity of 19.61%.

Bionano Genomics has a consensus price target of --, signalling upside risk potential of 396.77%. On the other hand Bruker has an analysts' consensus of $74.01 which suggests that it could grow by 29.77%. Given that Bionano Genomics has higher upside potential than Bruker, analysts believe Bionano Genomics is more attractive than Bruker.

Bionano Genomics has a beta of 2.279, which suggesting that the stock is 127.944% more volatile than S&P 500. In comparison Bruker has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.733%.

Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.35% to investors and pays a quarterly dividend of $0.05 per share. Bionano Genomics pays -- of its earnings as a dividend. Bruker pays out 6.88% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bionano Genomics quarterly revenues are $6.1M, which are smaller than Bruker quarterly revenues of $864.4M. Bionano Genomics's net income of -$44.2M is lower than Bruker's net income of $40.9M. Notably, Bionano Genomics's price-to-earnings ratio is -- while Bruker's PE ratio is 27.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.28x versus 2.60x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of -728.57% compared to Bionano Genomics's net margin of -21.86%. Bionano Genomics's return on equity of -158.95% beat Harvard Bioscience's return on equity of -20.42%.

Bionano Genomics has a consensus price target of --, signalling upside risk potential of 396.77%. On the other hand Harvard Bioscience has an analysts' consensus of -- which suggests that it could grow by 196.91%. Given that Bionano Genomics has higher upside potential than Harvard Bioscience, analysts believe Bionano Genomics is more attractive than Harvard Bioscience.

Bionano Genomics has a beta of 2.279, which suggesting that the stock is 127.944% more volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.272, suggesting its more volatile than the S&P 500 by 27.217%.

Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bionano Genomics pays -- of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend.

Bionano Genomics quarterly revenues are $6.1M, which are smaller than Harvard Bioscience quarterly revenues of $22M. Bionano Genomics's net income of -$44.2M is lower than Harvard Bioscience's net income of -$4.8M. Notably, Bionano Genomics's price-to-earnings ratio is -- while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.28x versus 0.93x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Revvity has a net margin of -728.57% compared to Bionano Genomics's net margin of 13.8%. Bionano Genomics's return on equity of -158.95% beat Revvity's return on equity of 3.24%.

Bionano Genomics has a consensus price target of --, signalling upside risk potential of 396.77%. On the other hand Revvity has an analysts' consensus of $138.47 which suggests that it could grow by 23.02%. Given that Bionano Genomics has higher upside potential than Revvity, analysts believe Bionano Genomics is more attractive than Revvity.

Bionano Genomics has a beta of 2.279, which suggesting that the stock is 127.944% more volatile than S&P 500. In comparison Revvity has a beta of 1.027, suggesting its more volatile than the S&P 500 by 2.691%.

Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revvity offers a yield of 0.25% to investors and pays a quarterly dividend of $0.07 per share. Bionano Genomics pays -- of its earnings as a dividend. Revvity pays out 5.05% of its earnings as a dividend. Revvity's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bionano Genomics quarterly revenues are $6.1M, which are smaller than Revvity quarterly revenues of $684M. Bionano Genomics's net income of -$44.2M is lower than Revvity's net income of $94.4M. Notably, Bionano Genomics's price-to-earnings ratio is -- while Revvity's PE ratio is 54.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.28x versus 5.10x for Revvity. Usually stocks with elevated PS ratios are considered overvalued.